Scattergun approach???? The acquisition of Azer-Cel made perfect sense for CF33 and the clinical trial data for VAXINIA, OASIS and Azer-Cel are still too early. That's why we are waiting for the second update for VAXINIA and Azer-Cel and first update for OASIS. BP will make their move end of Ph1 clinical trial which is expected end of this year so the data released in the next 3-6 months will be very telling to what happen end of this year.......
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)